This is a phase II, open label study that compares the efficacy of intravenous monthly iv. cyclophosphamide (NIH protocol) to high dose intravenous cyclophosphamide (immunoablative protocol) in the treatment of moderate to severe SLE. Patients will be followed for 24 months after therapy.

Project Start
1999-09-30
Project End
2004-09-29
Budget Start
1999-09-30
Budget End
2000-09-29
Support Year
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Petri, Michelle; Brodsky, Robert A; Jones, Richard J et al. (2010) High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum 62:1487-93